GlassScriptPhysician profile
Candice Bittinger
NPI 1962857300
$6,557.20
in general payments reported to CMS, 2019-2025
62 companies · $2,645 in 2025
The $2,645 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $785 · 2022: $787 · 2023: $1,351 · 2024: $989 · 2025: $2,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,915.49 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $834.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $433.28 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Pfizer INC. | $376.22 | 2021-2025 | |
| Janssen Biotech, INC. | $289.62 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $280.88 | 2021-2025 | Injectafer, Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $279.02 | 2021-2025 | Tagrisso, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $261.08 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Kite Pharma, INC. | $249.78 | 2021-2025 | Yescarta |
| Incyte Corporation | $219.65 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $175.46 | 2021-2023 | Tivdak |
| Bayer Healthcare Pharmaceuticals INC. | $173.85 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $148.83 | 2021-2025 | Reblozyl, Opdivo |
| Eisai INC. | $145.31 | 2021-2025 | |
| Abbvie INC. | $133.70 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $130.10 | 2022-2025 | Tazverik, Onivyde, Somatuline Depot |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Bittinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.